Send mail to Author

Correction : phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (Article)

Please indicate your contact information and select, which author you want to contact.



 
 __   _     ______   _____     __   __    _  __   __   __  
| || | ||  /_   _// |  __ \\   \ \\/ //  | |/ //  \ \\/ // 
| '--' ||   -| ||-  | |  \ ||   \ ` //   | ' //    \ ` //  
| .--. ||   _| ||_  | |__/ ||    | ||    | . \\     | ||   
|_|| |_||  /_____// |_____//     |_||    |_|\_\\    |_||   
`-`  `-`   `-----`   -----`      `-`'    `-` --`    `-`'
 


Back to frontdoor view

OPUS4 Logo